Detalhe da pesquisa
1.
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials.
Lancet Oncol
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38701815
2.
A comprehensive investigation of histotype-specific microRNA and their variants in Stage I epithelial ovarian cancers.
Int J Cancer
; 152(9): 1989-2001, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541726
3.
The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy.
J Med Virol
; 93(1): 537-540, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32633869
4.
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Int J Gynecol Cancer
; 31(6): 875-882, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33931498
5.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Int J Gynecol Cancer
; 31(10): 1348-1355, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462317
6.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Lancet Oncol
; 20(9): 1273-1285, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345626
7.
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
Br J Cancer
; 121(7): 584-592, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31434988
8.
ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer.
Breast Cancer Res Treat
; 175(2): 353-368, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30830488
9.
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 19(3): 295-309, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29449189
10.
High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Breast Cancer Res Treat
; 171(2): 261-271, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29845475
11.
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 17(8): 1114-1126, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27397040
12.
MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer.
Mol Carcinog
; 55(4): 357-65, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25630839
13.
LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis.
Gynecol Oncol
; 141(1): 121-7, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26751131
14.
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
Gynecol Oncol
; 143(3): 642-649, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27667152
15.
LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer.
Breast Cancer Res Treat
; 154(3): 473-82, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26564482
16.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol
; 15(4): 396-405, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24582486
17.
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Oncology
; 86(5-6): 351-8, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24942520
18.
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.
Am J Obstet Gynecol
; 210(4): 363.e1-363.e10, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24361787
19.
Prediction of recurrence risk in endometrial cancer with multimodal deep learning.
Nat Med
; 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38789645
20.
An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival.
Carcinogenesis
; 34(9): 2024-30, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23677070